Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05).
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4072-4072
◽
Keyword(s):
Phase Ii
◽